J. M. Agosti and S. J. Goldie, Introducing HPV Vaccine in Developing Countries ??? Key Challenges and Issues, New England Journal of Medicine, vol.356, issue.19, pp.1908-1910, 2007.
DOI : 10.1056/NEJMp078053

C. Allonier, P. Dourgnon, and T. L. Rochereau, Enquête Santé Protection Sociale 2006, un panel pour l'analyse des politiques de santé, la santé publique et la recherche en économie de la santé. Questions d'économie de la santé IRDES, pp.131-132, 2008.

S. Andersson, E. Rylander, and B. Larson, Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing, Oncology Reports, vol.10, pp.175-179, 2003.
DOI : 10.3892/or.10.1.175

F. Aubin, J. Prétet, and A. Jacquard, Human Papillomavirus Genotype Distribution in External Acuminata Condylomata: A Large French National Study (EDiTH IV), Clinical Infectious Diseases, vol.47, issue.5, pp.610-615, 2008.
DOI : 10.1086/590560

URL : https://hal.archives-ouvertes.fr/hal-00484954

O. Aynaud, Les comportements sexuels des consultants d'un centre de dépistage anonyme et gratuit du VIH à Paris, Contraception, vol.25, pp.242-250, 1997.

J. G. Baseman and L. A. Koutsky, The epidemiology of human papillomavirus infections, Journal of Clinical Virology, vol.32, pp.16-24, 2005.
DOI : 10.1016/j.jcv.2004.12.008

E. France and . Crisap, Bulletin Epidémiologique Hebdomadaire, pp.5-6, 2002.

H. J. Boot, I. Wallenburg, H. E. De-melker, and M. M. Mangen, Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands, Vaccine, vol.25, issue.33, pp.6245-6256, 2007.
DOI : 10.1016/j.vaccine.2007.05.061

F. X. Bosch, A. Lorincz, N. Muñoz, C. J. Meijer, and K. V. Shah, The causal relation between human papillomavirus and cervical cancer, Journal of Clinical Pathology, vol.55, issue.4, pp.244-265, 2002.
DOI : 10.1136/jcp.55.4.244

F. X. Bosch, M. M. Manos, and N. Muñoz, Prevalence of Human Papillomavirus in Cervical Cancer, Obstetrical & Gynecological Survey, vol.50, issue.10, pp.796-802, 1995.
DOI : 10.1097/00006254-199510000-00015

S. Boulenger, Guide méthodologique pour l'évaluation économique des stratégies de santé : recommandations méthodologiques. Collège des Economistes de la santé, 2003.

M. Bozon, At what age do women and men have their first sexual intercourse? World comparison and recent trends. Population and societies, pp.1-4, 2003.

M. Brisson, N. Van-de-velde, P. De-wals, and M. Boily, Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection, Canadian Medical Association Journal, vol.177, issue.5
DOI : 10.1503/cmaj.061709

M. Brisson, N. Van-de-velde, P. De-wals, and M. Boily, The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada, Vaccine, vol.25, issue.29, pp.5399-5408, 2007.
DOI : 10.1016/j.vaccine.2007.04.086

D. R. Brown, J. M. Schroeder, J. T. Bryan, M. H. Stoler, and K. H. Fife, Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients, Journal of Clinical Microbiology, vol.37, pp.3316-3322, 1999.

X. Castellsagué, S. De-sanjose, and T. Aguado, HPV and cervical cancer in the World, Report. Vaccine, vol.25, pp.1-230, 2007.

X. Castellsague and N. Munoz, Chapter 3: Cofactors in Human Papillomavirus Carcinogenesis--Role of Parity, Oral Contraceptives, and Tobacco Smoking, JNCI Monographs, vol.2003, issue.31, pp.20-28, 2003.
DOI : 10.1093/oxfordjournals.jncimonographs.a003477

P. E. Castle and A. R. Giuliano, Chapter 4: Genital Tract Infections, Cervical Inflammation, and Antioxidant Nutrients--Assessing Their Roles as Human Papillomavirus Cofactors, JNCI Monographs, vol.2003, issue.31, pp.29-34, 2003.
DOI : 10.1093/oxfordjournals.jncimonographs.a003478

C. Clavel, M. Masure, and J. Bory, Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women, British Journal of Cancer, vol.84, issue.12, pp.1616-1623, 2001.
DOI : 10.1054/bjoc.2001.1845

G. M. Clifford, S. Gallus, and R. Herrero, Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis, The Lancet, vol.366, issue.9490, pp.991-998, 2005.
DOI : 10.1016/S0140-6736(05)67069-9

G. M. Clifford, R. K. Rana, S. Franceschi, J. S. Smith, G. Gough et al., Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.5, pp.1157-1164, 2005.
DOI : 10.1158/1055-9965.EPI-04-0812

G. M. Clifford, J. S. Smith, T. Aguado, and S. Franceschi, Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis, British Journal of Cancer, vol.19, issue.1, pp.101-105, 2003.
DOI : 10.1016/S0140-6736(03)12120-4

G. M. Clifford, J. S. Smith, M. Plummer, N. Muñoz, and S. Franceschi, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, British Journal of Cancer, vol.88, issue.1, pp.63-73, 2003.
DOI : 10.1038/sj.bjc.6600688

J. T. Cox, The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?, Current Opinion in Obstetrics and Gynecology, vol.18, issue.Suppl 1, pp.5-13, 2006.
DOI : 10.1097/01.gco.0000216315.72572.fb

V. Dalstein, D. Riethmuller, and J. L. Sautière, Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus

D. Sanjose, S. Almirall, R. Lloveras, and B. , Cervical Human Papillomavirus Infection in the Female Population in Barcelona, Spain, Sexually Transmitted Diseases, vol.30, issue.10, pp.788-793, 2003.
DOI : 10.1097/01.OLQ.0000080177.82204.E0

D. Villiers, E. Fauquet, C. Broker, T. R. Bernard, H. Et-zur-hausen et al., Classification of papillomaviruses, Virology, vol.324, issue.1, pp.17-27, 2004.
DOI : 10.1016/j.virol.2004.03.033

J. Doorbar, The papillomavirus life cycle, Journal of Clinical Virology, vol.32, pp.7-15, 2005.
DOI : 10.1016/j.jcv.2004.12.006

E. H. Elbasha, E. J. Dasbach, and R. P. Insinga, Model for Assessing Human Papillomavirus Vaccination Strategies, Emerging Infectious Diseases, vol.13, issue.1, pp.28-41, 2007.
DOI : 10.3201/eid1301.060438

. Recommandations, Journal de gynécologie, obstétrique et biologie de la reproduction, pp.1-16, 1990.

E. L. Franco, L. L. Villa, J. P. Sobrinho, J. M. Prado, M. C. Rousseau et al., Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High???Risk Area for Cervical Cancer, The Journal of Infectious Diseases, vol.180, issue.5, pp.1415-1423, 1999.
DOI : 10.1086/315086

S. M. Garland, M. Hernandez-avila, and C. M. Wheeler, Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases, New England Journal of Medicine, vol.356, issue.19, pp.1928-1943, 2007.
DOI : 10.1056/NEJMoa061760

L. Gissmann and H. Z. Et-hausen, Human papilloma virus DNA: physical mapping and genetic heterogeneity., Proceedings of the National Academy of Sciences, vol.73, issue.4, pp.1310-1313, 1976.
DOI : 10.1073/pnas.73.4.1310

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC430256

J. D. Goldhaber-fiebert, N. K. Stout, J. A. Salomon, K. M. Kuntz, and S. J. Goldie, Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination, JNCI Journal of the National Cancer Institute, vol.100, issue.5, pp.308-320, 2008.
DOI : 10.1093/jnci/djn019

S. J. Goldie, . Shea, N. G. Campos, M. Diaz, S. Sweet et al., Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries, Vaccine, vol.26, issue.32, pp.4080-4093, 2008.
DOI : 10.1016/j.vaccine.2008.04.053

P. Hans-ulrich and . Research, From Natural History To Vaccines and Beyond. M. Saveria Campo Division of Pathological Sciences, 2006.

S. Hantz, S. Alain, and F. Denis, Vaccins prophylactiques antipapillomavirus??: enjeux et perspectives, Gyn??cologie Obst??trique & Fertilit??, vol.34, issue.7-8, pp.647-655, 2006.
DOI : 10.1016/j.gyobfe.2006.05.008

C. J. Haug, Human Papillomavirus Vaccination ??? Reasons for Caution, New England Journal of Medicine, vol.359, issue.8, pp.861-862, 2008.
DOI : 10.1056/NEJMe0804638

G. Y. Ho, R. Bierman, L. Beardsley, C. J. Chang, and R. D. Burk, Natural History of Cervicovaginal Papillomavirus Infection in Young Women, New England Journal of Medicine, vol.338, issue.7, pp.423-428, 1998.
DOI : 10.1056/NEJM199802123380703

A. Jacquard, F. Denis, J. Prétet, F. Aubin, P. Pradat et al., Distribution des génotypes de papillomavirus humain (HPV) dans les lésions génitales en France : études EDiTH, Bulletin Epidémiologique Hebdomadaire, pp.29-313, 2009.

E. Jougla, G. Pavillon, F. Rossollin, M. De-smedt, and J. Bonte, Improvement of the quality and comparability of causes-of-death statistics inside the European Community. EUROSTAT Task Force on "causes of death statistics, pp.447-456, 1998.

J. A. Kahn, D. Lan, and R. S. Kahn, Sociodemographic Factors Associated With High-Risk Human Papillomavirus Infection, Obstetrics & Gynecology, vol.110, issue.1, pp.87-95, 2007.
DOI : 10.1097/01.AOG.0000266984.23445.9c

J. J. Kim, M. Brisson, W. J. Edmunds, and S. J. Goldie, Modeling Cervical Cancer Prevention in Developed Countries, Vaccine, vol.26, pp.76-86, 2008.
DOI : 10.1016/j.vaccine.2008.06.009

J. J. Kim, J. Ortendahl, and S. J. Goldie, Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States, Annals of Internal Medicine, vol.151, issue.8, pp.538-545, 2009.
DOI : 10.7326/0003-4819-151-8-200910200-00007

A. Koulova, J. Tsui, K. Irwin, P. Van-damme, R. Biellik et al., Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006???January 2008, Vaccine, vol.26, issue.51, pp.6529-6541, 2006.
DOI : 10.1016/j.vaccine.2008.08.067

L. Koutsky, EPIDEMIOLOGY OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION, Epidemiologic Reviews, vol.10, issue.1, pp.3-8, 1997.
DOI : 10.1093/oxfordjournals.epirev.a036020

S. Kulasingam, L. Connelly, and E. Conway, A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program, Sexual Health, vol.4, issue.3, pp.165-175, 2007.
DOI : 10.1071/SH07043

S. L. Kulasingam and E. R. Myers, Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs, JAMA, vol.290, issue.6, pp.781-789, 2003.
DOI : 10.1001/jama.290.6.781

A. Lafuma, J. Monsonego, M. Moyal-barracco, and C. Pribil, Comparaison coût-efficacité par modélisation de l'imiquimod et de la podophyllotoxine dans le traitement du condylome acuminé externe en France, pp.731-736, 2003.

J. S. Lawson, W. K. Glenn, B. Heng, Y. Ye, B. Tran et al., Koilocytes indicate a role for human papilloma virus in breast cancer, British Journal of Cancer, vol.27, issue.8, pp.1351-1356, 2009.
DOI : 10.1038/nrc798

M. Lehtinen, D. Apter, and G. Dubin, Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing, International Journal of STD & AIDS, vol.17, issue.8, pp.517-521, 2006.
DOI : 10.1258/095646206778145550

H. X. Li, W. Y. Zhu, and M. Y. Et-xia, Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated in vitro CO2 laser, and microwave, Journal of Dermatological Science, vol.6, issue.1, pp.209-211, 1995.
DOI : 10.1016/0923-1811(93)91219-K

I. Lombard, A. Vincent-salomon, and P. Validire, Human papillomavirus genotype as a major determinant of the course of cervical cancer., Journal of Clinical Oncology, vol.16, issue.8, pp.2613-2619, 1998.
DOI : 10.1200/JCO.1998.16.8.2613

E. Lukasiewicz, S. Aractingi, and A. Flahault, Incidence et prise en charge des condylomes acuminés externes en médecine générale, pp.991-996, 2002.

L. E. Markowitz, E. F. Dunne, M. Saraiya, H. W. Lawson, H. Chesson et al., Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices, Morbidity and Mortality Weekly Report, vol.56, pp.1-24, 2007.
DOI : 10.1037/e601292007-001

L. R. Medeiros, D. D. Rosa, M. I. Da-rosa, M. C. Bozzetti, and R. R. Zanini, Efficacy of Human Papillomavirus Vaccines, International Journal of Gynecological Cancer, vol.17, issue.7, pp.1166-1176, 2009.
DOI : 10.1111/IGC.0b013e3181a3d100

J. Melnikow, J. Nuovo, A. R. Willan, B. K. Chan, and L. P. Howell, NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS, Obstetrics & Gynecology, vol.92, issue.Supplement, pp.727-735, 1998.
DOI : 10.1097/00006250-199810001-00046

J. Monsonégo, Pr??vention du??cancer du??col ut??rin??: enjeux et??perspectives de??la??vaccination antipapillomavirus, Gyn??cologie Obst??trique & Fertilit??, vol.34, issue.3, pp.189-201, 2006.
DOI : 10.1016/j.gyobfe.2006.01.036

J. Monsonego, Pr??vention du??cancer du??col ut??rin??: enjeux et??perspectives de??la??vaccination antipapillomavirus, Gyn??cologie Obst??trique & Fertilit??, vol.34, issue.3, pp.189-201, 2006.
DOI : 10.1016/j.gyobfe.2006.01.036

A. Moscicki, Impact of HPV infection in adolescent populations, Journal of Adolescent Health, vol.37, issue.6, pp.3-9, 2005.
DOI : 10.1016/j.jadohealth.2005.09.011

A. Moscicki, M. Schiffman, S. Kjaer, and L. L. Villa, Chapter 5: Updating the natural history of HPV and anogenital cancer, Vaccine, vol.24, pp.42-51, 2006.
DOI : 10.1016/j.vaccine.2006.06.018

N. Mubiayi, E. Bogaert, and F. Boman, Histoire du suivi cytologique de 148 femmes atteintes d???un cancer invasif du col ut??rin, Gyn??cologie Obst??trique & Fertilit??, vol.30, issue.3, pp.210-217, 2002.
DOI : 10.1016/S1297-9589(02)00297-7

K. Münger, B. A. Werness, N. Dyson, W. C. Phelps, E. Harlow et al., Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product, The EMBO Journal, vol.8, pp.4099-4105, 1989.

N. Muñoz, F. X. Bosch, and C. X. , Against which human papillomavirus types shall we vaccinate and screen? the international perspective, International Journal of Cancer, vol.183, issue.2, pp.278-285, 2004.
DOI : 10.1002/ijc.20244

N. Muñoz, F. X. Bosch, D. Sanjose, and S. J. , Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer, New England Journal of Medicine, vol.348, issue.6, pp.518-527, 2003.
DOI : 10.1056/NEJMoa021641

N. Muñoz, X. Castellsagué, D. González, A. B. Et-gissmann, and L. , Chapter 1: HPV in the etiology of human cancer, Vaccine, vol.24, pp.1-10, 2006.
DOI : 10.1016/j.vaccine.2006.05.115

A. F. Nicol, G. J. Nuovo, and J. Dillner, A summary of the 25th International Papillomavirus Conference 2009: Vaccines, screening, epidemiology and therapeutics, Journal of Clinical Virology, vol.47, issue.3, pp.208-215, 2010.
DOI : 10.1016/j.jcv.2009.12.005

O. Mondiale-de and L. Santé, Comité consultatif mondial de la sécurité vaccinale, 17-18 décembre, pp.37-40, 2008.

O. Mondiale-de and L. Santé, Vaccins anti-papillomavirus humain, note d'information de l'OMS. Relevé épidémiologique hebdomadaire, pp.118-131, 2009.

A. G. Ostör, Natural History of Cervical Intraepithelial Neoplasia, International Journal of Gynecological Pathology, vol.12, issue.2, pp.186-192, 1993.
DOI : 10.1097/00004347-199304000-00018

J. Paavonen, P. Naud, and J. Salmerón, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, The Lancet, vol.374, issue.9686, pp.301-314, 2009.
DOI : 10.1016/S0140-6736(09)61248-4

J. Peto, C. Gilham, and J. Deacon, Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort, British Journal of Cancer, vol.88, pp.942-953, 2004.
DOI : 10.1038/sj.bjc.6602049

M. Potocnik, B. J. Kocjan, K. Seme, and M. Poljak, Distribution of human papillomavirus (HPV) genotypes in genital warts from males in Slovenia, Acta Dermatovenerologica Alpina, vol.16, pp.91-96, 2007.

J. Prétet, A. Jacquard, and X. Carcopino, Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study, International Journal of Cancer, vol.367, issue.Suppl 3, pp.424-427, 2008.
DOI : 10.1002/ijc.23093

J. Prétet, A. Jacquard, and X. Carcopino, Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study, International Journal of Cancer, vol.367, issue.Suppl 3, pp.428-432, 2008.
DOI : 10.1002/ijc.23092

J. Prétet, A. Jacquard, and M. Saunier, Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2

L. Remontet, J. Estève, and A. Bouvier, Cancer incidence and mortality in France over the period 1978-2000. Revue d'épidémiologie et de Santé Publique, pp.3-30, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00427472

D. Riethmuller, J. P. Schaal, and C. Mougin, ??pid??miologie et histoire naturelle de l???infection g??nitale ?? papillomavirus humain, Gyn??cologie Obst??trique & Fertilit??, vol.30, issue.2, pp.139-146, 2002.
DOI : 10.1016/S1297-9589(01)00282-X

G. Riou, M. Favre, D. Jeannel, J. Bourhis, L. Doussal et al., Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA, The Lancet, vol.335, issue.8699, pp.1171-1174, 1990.
DOI : 10.1016/0140-6736(90)92693-C

B. Romanowski, D. Borba, P. C. Naud, and P. S. , Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine, analysis of a randomised placebo-controlled trial up to 6.4 years, Lancet, vol.374, pp.1975-1985, 2009.

M. Rosenheim, Vaccin contre les papillomavirus : Cibler les adolescentes de 14 ans, Concours médical 2007, pp.846-849

A. Rousseau, P. Bohet, J. Merlière, H. Treppoz, and B. Heules-bernin, Ancelle-Park R. Evaluation du dépistage organisé et du dépistage individuel du cancer du col de l'utérus : utilité des données de l'Assurance maladie, Bulletin Epidémiologique Hebdomadaire, pp.19-81, 2002.

M. Sant, T. Aareleid, and F. Berrino, EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary, Annals of Oncology, vol.14, issue.90005, pp.61-118, 2003.
DOI : 10.1093/annonc/mdg754

G. F. Sawaya, K. Smith-mccune, . Hpv, and . Vaccination, HPV Vaccination ??? More Answers, More Questions, New England Journal of Medicine, vol.356, issue.19, pp.1991-1993, 2007.
DOI : 10.1056/NEJMe078060

T. F. Schwarz, Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix??, Advances in Therapy, vol.26, issue.suppl.2, pp.983-998, 2009.
DOI : 10.1007/s12325-009-0079-5

J. S. Smith, L. Lindsay, and B. Hoots, Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update, International Journal of Cancer, vol.189, issue.3, pp.621-632, 2007.
DOI : 10.1002/ijc.22527

B. Swennen, Les vaccinations : rapport coût-efficacité. Revue Médicale de Bruxelles, pp.451-458, 2009.

A. V. Taira, C. P. Neukermans, and G. D. Sanders, Evaluating Human Papillomavirus Vaccination Programs, Emerging Infectious Diseases, vol.10, issue.11, pp.1915-1923, 2004.
DOI : 10.3201/eid1011.040222

URL : http://doi.org/10.3201/eid1011.040222

W. Techakehakij and R. D. Feldman, Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review, Vaccine, vol.26, issue.49, pp.6258-6265, 2008.
DOI : 10.1016/j.vaccine.2008.09.036

N. Thiry, M. Lambert, I. Cleemput, M. Huybrechts, M. Neyt et al., Vaccination HPV pour la prévention du cancer du col de l'utérus en Belgique: Health Technology Assessment, KCE report, vol.64, issue.152, 2007.

N. Van-de-velde, M. Brisson, and M. Boily, Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty, American Journal of Epidemiology, vol.165, issue.7, pp.762-775, 2007.
DOI : 10.1093/aje/kwk059

L. L. Villa, R. L. Costa, and C. A. Petta, High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up, British Journal of Cancer, vol.17, issue.11, pp.1459-1466, 2006.
DOI : 10.1093/aje/kwf180

V. Knebel-doeberitz and M. , New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections, European Journal of Cancer, vol.38, issue.17, pp.2229-2242, 2002.
DOI : 10.1016/S0959-8049(02)00462-8

V. Krogh and V. , Management of anogenital warts (condylomata acuminata), European Journal of Dermatology, vol.11, pp.598-603, 2001.

J. M. Walboomers, M. V. Jacobs, and M. M. Manos, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, The Journal of Pathology, vol.89, issue.1, pp.12-19, 1999.
DOI : 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

D. G. Walker, R. Hutubessy, and P. Beutels, WHO Guide for standardisation of economic evaluations of immunization programmes, Vaccine, vol.28, issue.11, pp.2356-2359, 2010.
DOI : 10.1016/j.vaccine.2009.06.035

S. S. Wang and A. Hildesheim, Chapter 5: Viral and Host Factors in Human Papillomavirus Persistence and Progression, JNCI Monographs, vol.2003, issue.31, pp.35-40, 2003.
DOI : 10.1093/oxfordjournals.jncimonographs.a003480

C. B. Woodman, S. Collins, and H. Winter, Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study, The Lancet, vol.357, issue.9271, pp.1831-1836, 2001.
DOI : 10.1016/S0140-6736(00)04956-4

N. Duport and J. Bloch, Dépistage du cancer du col de l'utérus, Baromètre cancer 2005. Editions Inpes. Inpes, pp.128-164, 2006.

F. Papillomaviridae, In : International Comittee on the Taxonomy of Viruses "Virus Taxonomy. Classification and nomenclature of viruses" 8 th report, pp.293-253, 2005.

J. Monsonégo, Infections à papillomavirus. État des connaissances, pratiques et prévention vaccinale, 2006.

J. Monsonégo, Traité des infections et pathologies génitales à papillomavirus, 2007.
DOI : 10.1007/978-2-287-72066-6

G. Orth, Les papillomavirus humains et leur r??le dans l???histoire naturelle du cancer du col de l???ut??rus. Perspectives dans le domaine de la pr??vention de ce cancer
DOI : 10.1007/2-287-28699-3_1

. Ouvrage-collectif, Place de la vaccination contre les papillomavirus humains en France, 2006.

A. Spira and N. Bajos, Les comportements sexuels en France. La documentation française, 1993.

K. J. Syrjänen, S. Syrjänen, and S. M. Syrjänen, Papillomavirus infections in human pathology, 2000.

C. Agence-de-la-santé-publique-du, Recommandations Relatives au Programme de Vaccination Contre le Virus du Papillome. Comité canadien d'immunisation, 2007.

A. Nationale-d, Accréditation en Santé, Anaes. Conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal, 2002.

A. Belot, M. Velten, and P. Grosclaude, Estimation nationale de l''incidence et de la mortalité par cancer en France entre, p.132, 1980.

D. Center, . Control, and . Prevention, Health Concerns Following HPV -Vaccine Safety, Atlanta. Advisory Committee on Immunization Practices (ACIP), pp.45-59, 2008.

C. Supérieur-d-'hygiène-publique-de-france, Avis relatif à la vaccination antipapillomavirus type 16 et 18, 2006.

C. Supérieur-d-'hygiène-publique-de-france, Avis relatif à la vaccination contre les papillomavirus humains 6, pp.16-18, 2007.

N. Duport, Données épidémiologiques sur le cancer du col de l'utérus, p.33, 2008.

J. P. Grünfeld, Plan Cancer, 2009.

H. Autorité and D. Santé, Note de cadrage : Stratégie de dépistage du cancer du col de l'utérus en France en, 2009.

D. Lévy-bruhl, Y. Kudjawv, . Invs-), B. Dervaux, and X. Lenne, Cresge) Modélisation médico-économique de l'impact de l'organisation du dépistage du cancer du col utérin et de l'introduction de la vaccination contre les HPV dans le calendrier vaccinal. InVS : Saint-Maurice, 2007.

U. Oms, Données mondiales sur la vaccination. Organisation Mondiale de la Santé, 2009.

O. and U. Et-banque-mondiale, Vaccins et vaccination: la situation dans le monde, 2009.

W. Bank, World development report 1993 : investing in health, 1993.

I. Zechmeister and B. Freiesleben-de-blasio, Okonomische Evaluation der Impfung gegen humane Papillomaviren (HPV-Impfung) in Osterreich. HTA Projektbericht n° 009, p.126, 2007.

A. European-medicines, EPARs for authorised medicinal products for human use. Cervarix. Disponible sur http, 2010.

A. European-medicines, EPARs for authorised medicinal products for human use. Gardasil. Disponible sur http, 2010.

U. Fdp-virologie, Disponible sur http://www.afd-ld.org/~fdp_viro/content.php?page=papillomavirus (dernière consultation mars, 2010.

U. Food and D. Administration, Vaccines and Related Biological Products Advisory Comitee meeting, 2009. Briefing information, 2009.